Microdosing GLP-1s for Inflammation Management?

A Houston gynecologist is telling patients that tiny, off-label doses of the same drugs driving America’s weight-loss boom might calm the chronic inflammation behind everything from brain fog to joint pain.

Story Snapshot

Dr. Susan Hardwick-Smith, a board-certified gynecologist and menopause specialist in Houston, promotes “microdosing” GLP-1 drugs like semaglutide for inflammation, not just weight loss.
Her protocol starts as low as 0.05 milligrams weekly, roughly one-tenth to one-fifth of a standard starting dose.
Published research already shows GLP-1 drugs lower inflammation markers such as C-reactive protein, but no large trials test her specific microdose approach.
Her Houston clinic runs a 12-week medically supervised GLP-1 microdosing program across three office locations.

A Different Use For A Familiar Drug Class

Semaglutide and tirzepatide made headlines as blockbuster weight-loss drugs. Sold under brand names like Ozempic and Mounjaro, they work by mimicking a gut hormone called GLP-1 that controls appetite and blood sugar. Dr. Hardwick-Smith argues these same drugs, taken at a fraction of the weight-loss dose, could target something different: the low-grade inflammation that quietly fuels chronic disease.

In a video posted to her YouTube channel, she describes her practice’s typical starting point as 0.05 milligrams of semaglutide weekly for four weeks, before any adjustment. That amount sits far below the 0.25 milligram starting dose doctors normally prescribe for weight management, putting her framework at roughly one-tenth to one-fifth of standard dosing.

What The Broader Research Actually Shows

Dr. Hardwick-Smith isn’t inventing the inflammation link out of thin air. A growing body of peer-reviewed science backs the idea that GLP-1 drugs fight inflammation, separate from any weight loss they cause. A 2024 systematic review found semaglutide lowered C-reactive protein, a key inflammation marker, across thirteen randomized trials covering more than 26,000 patients.

Other research has traced anti-inflammatory effects to specific biological pathways. Studies show GLP-1 drugs reduce activity in NF-κB, a molecular switch that triggers inflammation, and lower levels of TNF-alpha, a protein that drives tissue damage in chronic disease. Harvard Health has even reported reduced rates of heart failure, lung failure, and dementia among GLP-1 users compared to non-users.

How The Program Works In Practice

Dr. Hardwick-Smith runs her approach through the Complete Midlife Wellness Center, where she offers a 12-week, medically guided GLP-1 microdosing program described as delivering “a variety of anti-inflammatory benefits”. The clinic operates three Houston-area offices, plus remote visits, positioning the program as a supervised alternative to patients self-dosing without medical oversight.

Other practitioners in the same space report similar patient experiences, including reduced insulin-driven inflammation and improved energy at low doses without the harsh gastrointestinal side effects tied to full-strength GLP-1 treatment. These accounts remain anecdotal rather than clinically proven, but they echo a consistent theme: patients and doctors alike are exploring low-dose use ahead of formal trial data.

The Bottom Line For Patients Considering This Path

Chronic inflammation drives real, measurable harm, from arthritis to cardiovascular disease, and the mechanism behind GLP-1 drugs’ anti-inflammatory action has solid scientific backing. What’s missing is a large trial proving that microdoses, specifically, deliver that benefit safely and reliably. Patients weighing this option deserve straight talk: promising biology, real physician interest, but a treatment still ahead of its own proof.

For now, this remains a physician-led, off-label conversation rather than an approved standard of care. That distinction matters, and any patient considering it should have it explained clearly before starting treatment.